CJC-1295
A GHRH analog designed for long-acting stimulation of natural growth hormone production.
Overview
CJC-1295 is a synthetic GHRH (growth hormone-releasing hormone) analog. The DAC variant binds to albumin, dramatically extending its half-life and providing sustained elevation of GH and IGF-1 levels.
Benefits
- Increases natural GH and IGF-1 levels
- Supports lean muscle development
- May improve sleep architecture
- Often paired with Ipamorelin for synergy
Mechanism of Action
CJC-1295 binds to GHRH receptors on the anterior pituitary, stimulating the release of endogenous growth hormone in a pulsatile pattern. The DAC modification extends activity for several days.
Dosage (informational only)
- Typical range
- 100–300 mcg per dose
- Frequency
- 1–3x weekly (with DAC); daily without DAC
Frequently combined with a GHRP such as Ipamorelin to amplify GH pulses.
Side Effects
- Water retention or transient bloating
- Headache or flushing
- Tingling at injection site
Related peptides
A long-acting modified analog of insulin-like growth factor 1 with extended half-life and reduced binding-protein affinity.
A myostatin-binding protein studied for its potential to drive significant muscle hypertrophy by removing the body's natural growth ceiling.
A long-acting GLP-1 receptor agonist studied for its effects on appetite, satiety, and glucose regulation.